prostate cancer

Seven diseases benefiting from genetic tests
Seven diseases benefiting from genetic testsGenetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.
3 new FDA drug approvalsFDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.
PCa-specific mortality not affected by comorbidityComorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
BMI predicts post-RP metastasis, prostate cancer mortalityBody mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
Active surveillance linked with moderate anxietyMen undergoing active surveillance for prostate cancer experienced levels of anxiety that were moderate, but that decreased over time, according to results of a large, prospective cohort study presented at the 2017 Society of Urologic Oncology annual meeting in Washington.
Challenges remain for active surveillance in low-risk PCa“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
Top 9 peer-reviewed prostate cancer papers of 2017Multiparametric MRI, USPSTF’s updated PSA screening recommendation, and the landmark STAMPEDE and LATITUDE trials were among this year’s highlights in the peer-reviewed literature for prostate cancer, according to Leonard G. Gomella, MD; Stacy Loeb, MD, MS; and J. Brantley Thrasher, MD.
Study: Active surveillance uptake remains lowThe overall use of active surveillance in men with low-risk prostate cancer is 14.2%, according to an examination of the National Cancer Data Base.
Tissue-based PCa assays not robust to multifocalityTissue-based prognostic biomarker assays for prostate cancer are not robust to tumor multifocality and heterogeneity, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.